Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
HC-7366 by Hibercell for Metastatic Renal Cell Carcinoma: Likelihood of Approval
HC-7366 is under clinical development by Hibercell and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData,...
HC-7366 by Hibercell for Myelodysplastic Syndrome: Likelihood of Approval
HC-7366 is under clinical development by Hibercell and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I...
HC-7366 by Hibercell for Refractory Acute Myeloid Leukemia: Likelihood of Approval
HC-7366 is under clinical development by Hibercell and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...
HC-7366 by Hibercell for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
HC-7366 is under clinical development by Hibercell and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...
HC-7366 by Hibercell for Renal Cell Carcinoma: Likelihood of Approval
HC-7366 is under clinical development by Hibercell and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...